MARKET

INO

INO

Inovio Pharmaceu
NASDAQ
1.350
+0.020
+1.50%
After Hours: 1.330 -0.02 -1.48% 19:49 05/22 EDT
OPEN
1.315
PREV CLOSE
1.330
HIGH
1.450
LOW
1.315
VOLUME
3.32M
TURNOVER
--
52 WEEK HIGH
2.979
52 WEEK LOW
1.030
MARKET CAP
111.07M
P/E (TTM)
-0.7932
1D
5D
1M
3M
1Y
5Y
1D
Inovio gains on late-stage trial win for DNA shot
Seeking Alpha · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)
TipRanks · 2d ago
Inovio Pharmaceuticals Inc. Stock Advances 8.1%, Outperforms Peers
Dow Jones · 3d ago
Inovio: ApolloBio announces ‘positive’ results from Phase 3 trial of VGX-3100
TipRanks · 3d ago
Inovio Pharmaceuticals' Partner For VGX-3100 In China, ApolloBio, Announces Topline Results From Its Pivotal Phase 3 Trial Of VGX-3100; Trial Met Its Predefined Primary Efficacy Endpoint And Demonstrated An Overall Favorable Safety And Tolerability Profile
Benzinga · 3d ago
Inovio partner ApolloBio says VGX-3100 Phase 3 cervical dysplasia trial hits endpoint
PUBT · 3d ago
INOVIO PHARMACEUTICALS INC - VGX-3100 PHASE 3 TRIAL MEETS PRIMARY ENDPOINT WITH FAVORABLE SAFETY PROFILE
Reuters · 3d ago
Inovio Shareholders Endorse Governance Changes and Leadership
TipRanks · 4d ago
More
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Webull offers Inovio Pharmaceuticals Inc stock information, including NASDAQ: INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.